Currently, patients with non-small cell lung cancer receive erlotinib after chemotherapy and other drugs have failed. But erlotinib will only shrink the tumour about 10 per cent of the time.
"This is a step in the right direction that will allow us to eventually personalize a patient's treatment," says Queen's University Oncology professor Lesley Seymour, who was the coordinating physician on the study. "At the moment, we give drugs to patients and if they respond, we are happy and continue the treatment. If they don't, we move on to another drug."
In addition to helping doctors select the best drug treatment for patients, tests such as these will reduce exposure to medical side effects like rash and diarrhea caused by erlotinib, and eliminate financial burdens for a drug that may not benefit the patient. Newer drugs such as erlotinib can cost thousands of dollars for a month of treatment.
The current research is a follow-up to an erlotinib clinical trial between 2001 and 2005 at the Queen's University-based National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), which led to the approval of erlotinib in the treatment of non-small cell lung cancer.
In addition, blood and tissue samples collected in the original trials were used by David Carbone of the Vanderbilt-Ingram Cancer Center in Nashville to validate the blood tests. NCIC CTG and Queen's researchers also did the statistical analysis.
Professor Carbone presented his results on April 30 at the European Society for Medical Oncology Conference in Geneva, Switzerland.
Lung cancer is by far the deadliest form of cancer. There are 24,000 new cases of lung cancer diagnosed every year in Canada and 21,000 deaths.
Michael Onesi | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News